Sale by Ildstad Suzanne of 15713 shares of Talaris Therapeutics

TALSDelisted Stock  USD 2.98  0.10  3.25%   
Slightly above 61% of Talaris Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Talaris Therapeutics suggests that many traders are alarmed regarding Talaris Therapeutics' prospects. Talaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Talaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Talaris Therapeutics Inc director. General open market or private sale of non-derivative or derivative security

Read at macroaxis.com
Talaris insider trading alert for sale of common stock by Ildstad Suzanne, the corporate stakeholder, on 5th of June 2023. This event was filed by Talaris Therapeutics Inc with SEC on 2023-06-05. Statement of changes in beneficial ownership - SEC Form 4

Talaris Therapeutics Fundamental Analysis

We analyze Talaris Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

Talaris Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Talaris Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with similar companies.

Peers

Talaris Therapeutics Related Equities

CGEMCullinan Oncology   5.94   
0%
100.0%
TILInstil Bio   2.64   
0%
44.0%
ASMBAssembly Biosciences   1.71   
0%
28.0%
CTMXCytomX Therapeutics   0.92   
0%
15.0%
CNTBConnect Biopharma   0.11   
0%
1.0%
ACHLAchilles Therapeutics   0.10   
0%
1.0%
SPROSpero Therapeutics   0.01   
0%
1.0%
NXTCNextCure     
0%
1.0%
EWTXEdgewise Therapeutics   0.06   
1.0%
0%
OVIDOvid Therapeutics   0.10   
1.0%
0%
VORVor Biopharma   0.34   
5.0%
0%
NUVBNuvation Bio   0.37   
6.0%
0%
ACETAdicet Bio   1.02   
17.0%
0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets